Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401416 | 1.00 | ANPEP (0.42) | ANPEPLAP3PRSS1F2SLC6A2 | |
| SCHEMBL20401419 | 1.00 | ANPEP (0.42) | ANPEPLAP3PRSS1F2SLC6A2 | |
| SCHEMBL20764142 | 0.87 | ANPEP (0.50) | ANPEPLAP3PRSS1F2CYP3A4 | |
| SCHEMBL25255083 | 0.82 | ANPEP (0.34) | ANPEPLAP3PRSS1F2CYP2D6 | |
| SCHEMBL25255086 | 0.82 | ANPEP (0.34) | ANPEPLAP3PRSS1F2CYP2D6 | |
| SCHEMBL25255081 | 0.82 | ANPEP (0.34) | ANPEPLAP3PRSS1F2CYP2D6 | |
| SCHEMBL26447831 | 0.78 | ANPEP (0.50) | ANPEPLAP3PRSS1F2SLC6A2 | |
| SCHEMBL31423666 | 0.76 | ANPEP (0.37) | ANPEPLAP3 | |
| SCHEMBL31319430 | 0.75 | — | — | |
| SCHEMBL31319433 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| WO-2018136401-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | ANPEP 368/4885LAP3 221/4885PRSS1 121/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | ANPEP 368/4885LAP3 221/4885PRSS1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.